Cubist Recalls CUBICIN Vials Due to Glass Shard Presence
Cubist Pharmaceuticals is recalling 51,500 vials of CUBICIN (daptomycin) because a customer reported a glass shard in one vial.
The agency’s classification
FDA (Drugs): Class I
Class I is a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class I, which mandates a minimum severity score of 4 per the rubric.
Plain-English summary
Cubist Pharmaceuticals, Inc. is recalling 51,500 vials of CUBICIN (daptomycin for injection), 500 mg single-use vials. The recall was initiated after a customer complaint reported that one vial contained a glass shard.
The affected product is identified by Lot # 280453F with an expiration date of 04/16. The NDC is 67919-011-01 and the UPC is 3 67919-011-01 6. The product was distributed nationwide and in Puerto Rico.
Healthcare providers and patients should stop using the affected vials and contact the manufacturer or their supplier for further instructions.
The recalled product
- Product
- CUBICIN (daptomycin for injection), 500 mg single-use vial, Rx only, Manufactured for: Cubist Pharmaceuticals, Inc., Lexington, MA 02421, NDC 67919-011-01, UPC 3 67919-011-01 6.
- Manufacturer
- Cubist Pharmaceuticals, Inc.
- Category
- Drug — Injectable Antibiotic
- Affected units
- 51,500
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 280453F
- Exp 04/16
Distribution
Related recalls
Same manufacturer · Cubist Pharmaceuticals, Inc.
See all →- SevereCubicin Injection Recalled for Foreign Particulate Matter in Vials
FDA (Drugs) · 2014-11-05
- SevereCUBICIN daptomycin injection vials recalled due to potential glass particulate matter
FDA (Drugs) · 2014-10-08
- SevereCubicin Injection Recalled for Glass Particulates in Vials
FDA (Drugs) · 2014-01-29
Similar recalls
- SevereCubicin Injection Recalled for Glass Particulates in Vials
FDA (Drugs) · 2014-01-29
- SevereCUBICIN daptomycin injection vials recalled due to potential glass particulate matter
FDA (Drugs) · 2014-10-08
- SevereCubicin Injection Recalled for Foreign Particulate Matter in Vials
FDA (Drugs) · 2014-11-05
- SevereCubicin daptomycin injection recalled for glass particle contamination
FDA (Drugs) · 2021-11-10
- SeverePfizer Recalls Daptomycin Injection Due to Microbial Contamination
FDA (Drugs) · 2018-08-08
- SevereDoxorubicin liposome injection vials contain glass particulate matter
FDA (Drugs) · 2026-06-17